NBIX vs SNYR · P/E 45, rev $1.77B vs rev $30.4M
Neurocrine Biosciences Inc (NBIX) versus Synergy CHC Corp. Common Stock (SNYR) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Synergy CHC Corp. Common Stock (SNYR) is a medical distribution company listed on NASDAQ.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported SNYR revenue for 2025-12-31 was $30.4M. Net income was -$12.3M. Revenue was down 12.8% from 2024-12-31 to 2025-12-31. SNYR currently screens at market cap $2.9M.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. SNYR currently screens at market cap $2.9M.
Not investment advice. Open the NBIX and SNYR stock pages for the full models.
Not investment advice.